Heart Failure

Heart failure is when the heart fails to pump correctly in its severest form, causing dizziness, collapse, congestion of the lungs and risks of sudden death. There are many effective therapies for heart failure, delaying death and ameliorating symptoms. Yet, these are only available after diagnosis, and this is usually only when an extreme event has occurred. The sufferer has had to be admitted as an emergency to the hospital with life-threatening lung congestion and severe shortness of breath.

Pre-Heart Failure (Pre-HF)

Most recently, with significant new detection and precision
drug treatments becoming available, revised stages of
Heart Failure has been proposed by the European Society of
Cardiology. The proposed stages will enhance clinician, patient and public understanding and adoption, to avoid the stigma of HF before the symptoms are manifest. It will address the evolving role of biomarkers to define patients with structural and sub-clinical heart disease who are at higher risk of developing Heart Failure, the Pre-HF stage, are potential candidates for targeted treatment strategies for the prevention of Heart Failure.

Heart Failure with

Preserved Ejection Fraction (HFpEF)

HFpEF currently represents approximately 50% of Heart
Failure (HF) cases, is common and associated with high morbidity and mortality. Understanding the epidemiology of HFpEF has been difficult due to the challenges in HFpEF diagnosis and physiological processes associated that underlie HFpEF. Diagnosis under the current system involves multiple tests; including different types of echocardiography
imaging and invasive cardiac catherisation. Other diagnostic investigations include electrocardiography (LV hypertrophy, atrial fibrillation, ischemia) and chest radiograph (pulmonary venous congestion). Stress testing (myocardial ischemia), coronary angiography (coronary artery disease), or Holter ECG monitoring (paroxysmal arrhythmias, rate control) may be indicated.

Conventional Heart Failure Tests
Heart Failure Statistics